Biomedical Systems

Biomedical Systems Corporation was a clinical research services and medical technology company founded in 1975 by W. Raymond Barrett. Based in Maryland Heights, Missouri, it supported pharmaceutical and biotechnology development programs by collecting, managing, analyzing, and distributing specialized clinical data. Its principal areas included centralized cardiac-safety assessment, medical imaging, respiratory endpoint services, and electronic patient-reported outcomes, commonly known as ePRO. The company operated at the intersection of contract research and diagnostic technology. Rather than functioning as a conventional hospital system or a consumer medical-device brand, Biomedical Systems supplied infrastructure and specialist services used by biopharmaceutical sponsors and contract research organizations across clinical-development programs. Its work could span multiple phases of research and included the acquisition and interpretation of physiological and imaging data needed to assess the safety or efficacy of investigational therapies. Biomedical Systems also developed technology for remote cardiac monitoring. In 2010 it introduced the TruVue Wireless Telemetry Device, a wireless ambulatory electrocardiogram system designed to record and transmit heartbeat data for periods of up to 30 days. The system was intended to support the diagnosis and management of atrial fibrillation and other cardiac arrhythmias. TruVue formed part of the company's Cardiac Patient Services business and illustrated its combination of clinical operations with proprietary monitoring technology. The company expanded its electronic patient-reported-outcome capabilities in 2012 through the acquisition of Symfo, a Belgium-based provider. This added ePRO services to its existing cardiac, imaging, and respiratory offerings and broadened the range of patient data that it could collect in clinical research. Biomedical Systems maintained an international presence, with locations or operations identified in Brussels, Tsukuba, Pondicherry, and Beijing in addition to its United States headquarters. Biomedical Systems subsequently reduced its direct physician- and hospital-based cardiology testing activities. In April 2014, it sold that unit, including the TruVue-related business, to BioTelemetry for approximately $8.65 million in cash and stock. The transaction represented a shift toward its centralized clinical-trial services while transferring a patient-monitoring operation to a company focused on remote cardiac diagnostics. On September 8, 2017, ERT announced that it would acquire Biomedical Systems. The acquisition placed Biomedical Systems within a larger provider of technology-enabled clinical research services. After ERT merged with Bioclinica, the combined parent was rebranded as Clario in 2021. Biomedical Systems is therefore best understood as a former specialized clinical-trial-services brand whose capabilities were incorporated into successor organizations rather than as an active standalone hospital or medical-device company. The company was also involved in a significant commercial dispute with GE Marquette Medical Systems. In 2002, the United States Court of Appeals for the Eighth Circuit affirmed a jury verdict awarding Biomedical Systems $75 million in a breach-of-contract case concerning the FDA-clearance strategy for a home uterine-activity monitor.

Biomedical Systems was established in 1975 by W. Raymond Barrett and developed as a specialized provider to the clinical research and pharmaceutical industries. Its core model centered on centralized services: clinical data and physiological signals could be collected through distributed sites, processed by specialist teams, and returned to sponsors in a standardized form for use in drug-development programs. The company focused particularly on cardiac safety, medical imaging, respiratory endpoints, and later electronic patient-reported outcomes. Its cardiac activities included both service operations and monitoring technology. In 2010, Biomedical Systems introduced the TruVue Wireless Telemetry Device, a wireless ambulatory ECG system capable of recording and remotely transmitting heartbeat information for up to 30 days. The device was designed for the assessment and management of atrial fibrillation and other arrhythmias. This product complemented the company's Cardiac Patient Services business but was later transferred to BioTelemetry as part of a broader divestiture. Biomedical Systems expanded internationally and established a European headquarters in Brussels in 1981. Locations or operations were also associated with Tsukuba, Japan, Pondicherry, India, and Beijing, China, where the company worked through a partnership. In 2012, its acquisition of Symfo, a Belgium-based company, added electronic patient-reported outcomes to its portfolio. The expansion enabled Biomedical Systems to support the collection of patient-reported data in electronic form and across different modalities during clinical research. In April 2014, Biomedical Systems sold its physician- and hospital-based cardiology testing unit to BioTelemetry for approximately $8.65 million in cash and stock. The transaction included the business associated with TruVue and reduced the company's exposure to direct cardiology testing in physician and hospital settings. Its remaining identity was increasingly tied to centralized clinical-trial services and technology-enabled data operations for biopharmaceutical sponsors and contract research organizations. ERT announced the acquisition of Biomedical Systems on September 8, 2017. The deal integrated Biomedical Systems' specialized services into ERT's broader clinical research technology platform. ERT later merged with Bioclinica, and the combined organization adopted the Clario name in 2021. As a result, Biomedical Systems no longer operated as an independent standalone company, although its capabilities were incorporated into the successor business. Biomedical Systems' history also includes a major contract dispute. In 2002, the Eighth Circuit affirmed a jury award of $75 million in the company's breach-of-contract case against GE Marquette Medical Systems. The dispute concerned the FDA-clearance strategy for a home uterine-activity monitor. This legal matter is notable in the company's corporate history because it involved the commercialization and regulatory pathway of medical-monitoring technology.

1. 2021Successor organization adopts the Clario name

   After ERT merged with Bioclinica, the combined parent company rebranded as Clario.

   Source
2. 2017ERT announces acquisition

   ERT announced its acquisition of Biomedical Systems on September 8, 2017.

   Source
3. 2014Cardiology testing unit sold to BioTelemetry

   Biomedical Systems sold its physician- and hospital-based cardiology testing unit to BioTelemetry for approximately $8.65 million in cash and stock.

   Source
4. 2012Symfo acquisition expands ePRO services

   The acquisition of Belgium-based Symfo added electronic patient-reported outcome capabilities to Biomedical Systems' clinical research portfolio.

   Source
5. 2010TruVue wireless telemetry system introduced

   Biomedical Systems introduced the TruVue Wireless Telemetry Device for extended ambulatory ECG recording and remote transmission.

   Source
6. 2002Eighth Circuit affirms contract verdict

   The United States Court of Appeals for the Eighth Circuit affirmed a jury award of $75 million to Biomedical Systems in its dispute with GE Marquette Medical Systems.

   Source
7. 1981European headquarters established in Brussels

   The company established a European headquarters in Brussels, Belgium, supporting its international clinical research activities.

   Source
8. 1975Biomedical Systems is founded

   W. Raymond Barrett founded Biomedical Systems in the United States as a provider of specialized medical and clinical research services.

   Source

A specialist clinical-trial-services provider combining centralized physiological and imaging data operations with medical-monitoring technology and electronic patient-reported outcomes for biopharmaceutical sponsors and contract research organizations.

• TruVue Wireless Telemetry DeviceCardiac monitoring technology2010

  A wireless ambulatory ECG monitoring system introduced in 2010. TruVue could record and remotely transmit heartbeat data for up to 30 days and was intended to support the diagnosis and management of atrial fibrillation and other cardiac arrhythmias. The product was associated with Biomedical Systems' Cardiac Patient Services business and was later transferred to BioTelemetry in the 2014 sale of the cardiology testing unit.

• Centralized cardiac safety servicesClinical-trial service

  Specialized cardiac data collection, analysis, and reporting services for pharmaceutical and biotechnology clinical-development programs. These services formed one of Biomedical Systems' principal areas of activity and were designed to help sponsors evaluate cardiac safety during drug research.

• Medical imaging servicesClinical-trial service

  Centralized medical-imaging support for clinical research, including the collection, management, and analysis of imaging endpoints. Biomedical Systems supplied these capabilities to biopharmaceutical sponsors and contract research organizations as part of its broader clinical-trial-services portfolio.

• Respiratory endpoint servicesClinical-trial service

  Services supporting respiratory measurements and endpoints in drug-development studies. The offering complemented Biomedical Systems' cardiac and imaging operations and contributed specialized clinical data to studies conducted for biopharmaceutical sponsors.

• Electronic patient-reported outcomesClinical data service2012

  Electronic patient-reported outcome services for collecting, analyzing, and distributing patient-generated clinical data in multiple formats and across clinical research phases. Biomedical Systems expanded this capability through its 2012 acquisition of Symfo, a Belgium-based provider.

• 2017Join ERT's clinical research technology platformM&A

  Biomedical Systems had developed a portfolio spanning cardiac safety, imaging, respiratory endpoints, and ePRO services for clinical research.

  What changed. ERT announced the acquisition of Biomedical Systems on September 8, 2017.

  Aftermath. Biomedical Systems' capabilities were incorporated into ERT and later into the Clario organization after ERT's merger with Bioclinica.

  Source
• 2014Divest physician- and hospital-based cardiology testingStrategy

  Biomedical Systems operated both centralized clinical-trial services and a physician- and hospital-based cardiology testing unit, including the TruVue-related monitoring business.

  What changed. The company sold the cardiology testing unit to BioTelemetry for approximately $8.65 million in cash and stock.

  Aftermath. The sale shifted Biomedical Systems away from direct cardiology testing and toward its centralized clinical research services.

  Transaction consideration. $8.65 million (April 2014)

  Source
• 2012Acquire Symfo to expand into ePROM&A

  Biomedical Systems' established portfolio focused on centralized cardiac, imaging, and respiratory services, while electronic patient-reported outcomes offered an adjacent clinical-data capability.

  What changed. The company acquired Belgium-based Symfo and added electronic patient-reported outcome services to its offering.

  Aftermath. The transaction broadened Biomedical Systems' clinical research platform and international capabilities.

  Source

• 2021ERT and Bioclinica combination leads to Clario rebrand

  Following ERT's merger with Bioclinica, the combined parent company adopted the Clario name. Biomedical Systems' capabilities consequently became part of a successor clinical research technology organization.

  M&ALeadership changeOther
  Source
• 2017ERT announces acquisition of Biomedical Systems

  ERT announced on September 8, 2017 that it would acquire Biomedical Systems, bringing the company's cardiac safety, imaging, respiratory, and ePRO capabilities into a larger clinical research technology platform.

  M&A
  Source
• 2014Biomedical Systems sells cardiology testing unit to BioTelemetry

  The company sold its physician- and hospital-based cardiology testing unit to BioTelemetry for approximately $8.65 million in cash and stock. The divested activities included the TruVue-related cardiac monitoring business.

  M&A
  Source
• 2012Biomedical Systems acquires Symfo to add electronic patient-reported outcomes

  Biomedical Systems acquired Belgium-based Symfo, expanding its clinical research portfolio with electronic patient-reported outcome services.

  M&A
  Source
• 2010Biomedical Systems introduces TruVue wireless ambulatory ECG monitoring system

  Biomedical Systems launched its TruVue Wireless Telemetry Device for remote recording and transmission of heartbeats for up to 30 days, targeting atrial fibrillation and other cardiac arrhythmias.

  Product launchProduct generation
  Source
• 2002Court affirms $75 million Biomedical Systems contract verdict against GE Marquette

  The United States Court of Appeals for the Eighth Circuit affirmed a jury verdict awarding Biomedical Systems $75 million in a breach-of-contract dispute involving the FDA-clearance strategy for a home uterine-activity monitor.

  LawsuitOther
  Source

1. Biomedical Systems